¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼¼ºê¶õ½ºº´¿ø ´ëÇÑÇ÷¾×ÇÐȸ AML/MDS ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼¼ºê¶õ½ºº´¿ø ´ëÇÑÇ÷¾×ÇÐȸ AML/MDS ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-15
±³À°ÀÏÀÚ : 2018-09-15
±³À°Àå¼Ò : ¼¼ºê¶õ½ºº´¿ø Á¾ÇÕ°ü 337È£ °­ÀǽǠ 
±³À°ÁÖÁ¦ : AML/MDS ¿¬±¸È¸ ½ÉÆ÷Áö¾ö      
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : AML/MDS¿¬±¸È¸  
´ã´çÀÚ : Á¤¼¼¿µ
¿¬¶ôó : 02-533-1408  
À̸ÞÀÏ : seiyoung@yuhs.ac      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 60¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 25ºÐ  
¼¼ºÎ¼ö°­·á : 0¿ø      
ºñ°í       
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 09:50~10:20 Long term use of hypomethylating agents for MDS  Á¤ÁØ¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 10:20~10:50 JALSG AML/MDS/CMML Clinical observational study -Preliminary report of the MDS part-  Kensuke Usuki(NTT Medical Center Tokyo) 
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 10:50~11:20 Genetic mutations and decision-making of treatment options for MDS  ±èÀ¯Áø(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 11:20~11:50 Preliminary report of AZA trial for high risk MDS, MDS212 on behalf of JALSG  Yasushi Miyazaki(Nagasaki University) 
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 11:50~12:05 Study Proposal (I)- Prospective study of the indUction Regimen for acute non-Promyelocytic myeloid Leukemia in Elderly Hypomethylating agents for favorable risk (PURPLE-H)   ±èÇõ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 12:05~12:20 Study Proposal (II) - Beyond hypomethylating agent (HMA) failure in AML patients  ¹Ú½Çºñ¾Æ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 12:20~12:35 Study Proposal (III) - Comparative study on MDS between Korea and Japan  Yasushi Miyazaki(Nagasaki University) 
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 13:30~13:55 Decision between epigenetic therapy and chemotherapy in patients with AML  ÀÌÇý¿ø(±¹¸³¾Ï¼¾Å¸) 
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 13:55~14:20 Genomics of Myeloid Malignancies  Á¶¿µ¿í(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 14:30~14:55 Target Therapy  ½Åµ¿¿±(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09¿ù 15ÀÏ Á¾ÇÕ°ü 337È£ 14:55~15:20 CAR-T Therapy, Immune Checkpoint and Vaccine Approaches in AML  ÀåÁØÈ£(¼º±Õ°üÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼¼ºê¶õ½ºº´¿ø ´ëÇÑÇ÷¾×ÇÐȸ AML/MDS ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑôÃ߽Űæ¿Ü°úÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ : 2018-09-15
´ÙÀ½±Û °í·Á´ëÇб³ ±¸·Îº´¿ø Çѱ¹ÀÇ·áÀ±¸®ÇÐȸ ÀÇ»çÁ÷À» À§ÇÑ ÀÇ·áÀ±¸® ½ÉÆ÷Áö¾ö : 2018-09-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20702 ´ë±¸ Çѱ¹¿©ÀÚÀÇ»çȸ ´ë±¸°æºÏÁöȸ 5¿ù Çмú½ÉÆ÷Áö¾ö : 2024-05-28 0 39 2024-05-25
20701 ¼­¿ï Áß±¸ÀÇ»çȸ 2024³â Á¦1Â÷ ȸ¿ø ¿¬¼ö±³À°(°ñ´Ù°ñÁõ ÃÖ½ÅÄ¡·á, Æó·Å±¸±Õ ¹é½Å) : 2024-05-28 0 74 2024-05-25
20700 ºÎ»ê Çѱ¹¿©ÀÚÀÇ»çȸ ºÎ»êÁöȸ 5¿ù Çмú½ÉÆ÷Áö¾ö : 2024-05-28 1 50 2024-05-25
20699 ´ëÀü Á¦ 4ȸ ´ëÇÑ»êºÎÀΰúÃÊÀ½ÆÄÇÐȸ ÃæûÁöȸ ¿¬¼ö°­Á : 2024-05-26 0 88 2024-05-25
20698 ¼­¿ï 2024³â ´ëÇѳëÀκ´ÇÐȸ Á¦73Â÷ Çмú´ëȸ(Ãá°è)(2ÀÏÂ÷) : 2024-05-26 0 66 2024-05-25
20697 ¼­¿ï (¿Â¶óÀÎ) 2024³â ±âº» ¼Ò¾Æ ÀÀ±Þ óġ ±³À°°úÁ¤ 1Â÷(BPECC) : 2024-05-26 0 31 2024-05-25
20696 Ãæ³² Á¦ 28ȸ ¼øõÇâ ºñ´¢ÀÇÇаú ½ÉÆ÷Áö¿ò(2ÀÏÂ÷) : 2024-05-26 0 25 2024-05-25
20695 Ãæ³² Á¦16Â÷ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­ ±³À° (»ó¹Ý±â_1ÀÏÂ÷) : 2024-05-26 0 40 2024-05-25
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 202 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 79 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 122 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 123 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 134 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 163 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 93 2024-05-11
31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷